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Rethinking the Potential Roles of Mast
Cells in Skin Wound Healing and
Bleomycin-Induced Skin Fibrosis
Stephen J. Galli1,2
Skin wound healing and bleomycin-induced skin fibrosis are thought to reflect
complex interactions among diverse cell types. Several lines of evidence have
implicated mast cells in these tissue responses. However, data from Willenborg
et al. (this issue) and from three other groups suggest that, in at least these
examples of cutaneous tissue remodeling, mast cells may not have nonredundant
roles.
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Identifying the contributions of indi-
vidual cells to complex biological
responses that involve interactions
among many different cell types
can be challenging. Finding that such
processes are associated with changes
in the numbers, anatomical distri-
butions, and/or activation of specific
cells suggests that they have critical
roles in the biological responses; how-
ever, such data alone do not reveal the
nature or importance of such ‘‘potential
contributions’’. In this issue, Willenborg
et al. (2014) provide strong evi-
dence that, despite hypotheses to the
contrary, mast cells do not contribute
importantly to features of a model
of cutaneous wound healing or to
bleomycin-induced skin fibrosis. These
data add to earlier reports (Yamamoto
et al., 1999; Antsiferova et al., 2013;
Nauta et al., 2013) that, in models of
skin wound healing (Antsiferova et al.,
2013; Nauta et al., 2013; Willenborg
et al., 2014) or bleomycin-induced skin
fibrosis (Yamamoto et al., 1999;
Willenborg et al., 2014), the nature of
the mast cell’s contributions, if any,
remain to be determined.
Why were mast cells thought to
contribute to skin wound healing and
bleomycin-induced fibrosis in the
first place?
As reviewed elsewhere (Yamamoto
et al., 1999; Weller et al., 2006; Ng,
2010; Antsiferova et al., 2013; Nauta
et al., 2013; Willenborg et al., 2014),
there has been much speculation that
mast cells have important roles in
wound healing, especially in its early
phases, when inflammation and
angiogenesis help to clear ‘‘debris’’
and deliver nutrients to the wound
bed. Such speculation is based on
several lines of evidence, including
morphological findings indicating that
various models of skin wound healing
can be associated with changes in the
numbers, tissue distributions, and/or
function of mast cells at that site, and
on data from in vitro or pharmacological
studies, which have indicated that a
wide variety of mediators produced by
mast cells (and, in most cases, by
several other types of cells also)
have functions that may contribute to
wound healing or to bleomycin-induced
fibrosis.
Why was this evidence insufficient to
prove that mast cells, in fact, contributed
to such responses?
In complex biological processes, one
cannot be certain of what an individual
element contributes unless it is possible
to delete that element. Ideally, one
would study the response in animals
that differ only in having or lacking the
element in question, and/or by using an
intervention (e.g., drug, antibody) whose
only effect would be to remove or
neutralize such an element. In the case
of mast cells, there is no known drug or
antibody whose only effect is to elim-
inate or ablate their function alone (see
Oka et al. (2012)). Although there are
no reported mouse strains in which the
sole defect is a profound depletion of
all populations of mast cells, several
genetically modified mast cell–deficient
mouse strains are available. These have
been used to investigate biological res-
ponses in the presence or virtual absence
of mast cells (Reber et al., 2012;
Rodewald and Feyerabend, 2012).
What have we learned from mast
cell–deficient mice?
As noted by Weller et al. (2006), Nauta
et al. (2013), Antsiferova et al. (2013),
and Willenborg et al. (2014), several
studies have suggested that mast cells
contribute to various aspects of skin
wound healing in mice by comparing
findings in kit-mutant, mast cell–deficient
mice (usually (WBxC57BL/6)F1-Kit
W/W-v
mice) with those in wild-type control
mice; however, only one of these stu-
dies demonstrated that the abnormalities
observed in the mast cell–deficient mice
were eliminated if they were engrafted
with in vitro-derived mast cells at sites
later subjected to wounding (Weller
et al., 2006). Weller et al. (2006) found
that acute enhancement of vascular
permeability at sites of full-thickness
wounds was diminished, closure of the
wounds was delayed, and infiltration of
neutrophils at such sites was reduced in
mast cell–deficient KitW/W-v mice, and
these abnormalities were not observed
in the same type of mice after engraft-
ment on the skin with in vitro-derived
mast cells 4 weeks earlier. However, as
noted by Weller et al. (2006) and
others (reviewed in Reber et al. (2012)
and Rodewald and Feyerabend (2012)),
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c-kit mutant mice have several
phenotypic abnormalities in addition
to their mast cell deficiency, and, in
KitW/W-v mice, one of these is reduced
levels of blood neutrophils. Now that
experiments can be performed using
mice with constitutive or inducible
mast cell deficiency, but without muta-
tions affecting c-kit structure or expres-
sion (Reber et al., 2012; Rodewald
and Feyerabend, 2012), it is possible
to allay concerns that the results of
wound healing experiments comparing
wild-type with c-kit mutant mice may
reflect abnormalities in the kit-mutant
mice other than their mast cell
deficiency.
Two earlier studies examined skin
wound healing in mice that were mast
cell–deficient independently of muta-
tions affecting c-kit structure or expres-
sion. Nauta et al. (2013) showed that
each of the three kinds of mast cell–
deficient mice studied, C57BL/6-KitW-sh/
W-sh mice, (WBxC57BL/6)F1-Kit
W/W-v
mice, and Cpa3-Cre; Mcl-1fl/fl mice
(which are mast cell–deficient by a
c-kit-independent mechanism (Lilla
et al., 2011)), re-epithelialized splinted
excisional skin wounds at rates very
similar to those in the corresponding
wild-type or control mice. Moreover, at
the time of wound closure, scars were
similar in the three types of genetically
modified mast cell–deficient mice and
in the corresponding wild-type or con-
trol mice in regard to both quantity of
collagen deposition and maturity of
collagen fibers, as evaluated by Mas-
son’s Trichrome and picrosirius red
staining. Because the skin wounds ana-
lyzed were splinted specifically to inhi-
bit wound contraction, this model is not
suitable for evaluating any possible
effects of mast cells on wound contrac-
tion as opposed to re-epithelialization.
Antsiferova et al. (2013) used the
imaginatively named ‘‘CreMaster’’ mast
cell–deficient mice, which are mast cell
deficient because of Cre-related geno-
toxicity in the mast cell lineage (based
on their high levels of expression of
Cpa3), to analyze several features of
unsplinted full-thickness skin wounds.
Compared with (CD1xC57BL/6)F1 con-
trol mice, (CD1xC57BL/6)F1-CreMaster
mice exhibited no significant abnormal-
ities in the kinetics of back skin wound
closure (including soon after wounding),
wound myeloperoxidase (MPO) acti-
vity at day 1 of wounding, % wound
coverage by neo-epithelium, or area of
wound granulation tissue at 5 days after
wounding. In contrast to the analysis of
(WBxC57BL/6)F1-Kit
W/W-v and -Kitþ /þ
mice by Weller et al. (2006), the work in
(CD1xC57BL/6)F1-CreMaster and control
mice revealed no evidence for a role
of mast cells either in early wound
contraction or in early infiltration of
the skin by MPOþ cells.
Regarding the model of bleomycin-
induced skin fibrosis, Yamamoto et al.
(1999) showed that daily subcutaneous
injection of bleomycin for 4 weeks
induced similar levels of skin fibrosis
in (WBxC57BL/6)F1-Kit
W/W-v (mast cell–
deficient) and -Kitþ /þ (wild-type con-
trol) mice, as judged either by histolo-
gical analysis or by skin hydroxyproline
content. However, fibrosis was detect-
able histologically at week 1 in the wild-
type mice but not until week 2 in the
KitW/W-v mice. Bleomycin injections
also induced increased numbers of skin
mast cells in the wild-type mice but not
in the KitW/W-v mice. Yamamoto et al.
(1999) concluded that mast cells are not
required for the development of skin
fibrosis in this model, but that they
may hasten the process.
How have the findings of Willenborg
et al. advanced our understanding?
Willenborg et al. (2014) reinvestigated
the role of mast cells in the healing of
full-thickness skin wounds, and in the
development of bleomycin-induced skin
fibrosis, using a different, very attractive,
genetic model (i.e., the C57BL/6-
Mcpt5Cre/iDTR mouse). In these mice,
administration of diphtheria toxin (DT)
induces a profound mast cell deficiency
in the skin, in which mast cells express
the protease Mcpt5. They found little
difference between mice with normal
and mice with profoundly diminished
populations of skin mast cells by assess-
ing several features of skin wound
healing responses. (One exception was
that the mast cell–deficient mice exhib-
ited a significant, albeit modest, delay in
the closure of ends of the panniculus
carnosus at wound edges.) They also
found no significant difference between
mast cell–deficient and control mice in
bleomycin-induced increases in dermal
thickness, or in histochemical or bio-
chemical features of the collagen
deposited at sites of skin fibrosis, as
assessed at either 2 or 4 weeks after
the onset of bleomycin treatment. As
in the study by Yamamoto et al. (1999),
bleomycin treatment increased the
number of mast cells at sites of skin
fibrosis in DT-treated C57BL/6-iDTR
control mice but not in DT-treated
mast cell–deficient C57BL/6-Mcpt5Cre/
iDTR mice.
Can we conclude that mast cells ‘‘make
no contribution’’ to skin wound healing
or bleomycin-induced skin fibrosis?
No, because of the following reasons.
First, other models of skin wound heal-
ing, or other protocols for inducing skin
fibrosis with bleomycin, may reveal con-
tributions of mast cells that were not
seen previously. Given the results that
have already been reported (Yamamoto
et al., 1999; Antsiferova et al., 2013;
Nauta et al., 2013; Willenborg et al.,
2014), whether one would want to
invest the energy and money to con-
tinue to search for other models of skin
wound healing or different protocols for
Clinical Implications
 In humans and other mammals, skin wound healing and bleomycin-
induced tissue fibrosis can be associated with changes in the numbers
and/or the anatomical distribution of mast cells.
 Mast cells can produce many mediators, which have the potential to
influence wound healing and tissue fibrosis.
 Studies using mice with a constitutive or inducible depletion of mast cell
populations question whether mast cells can make critical nonredundant
contributions to skin wound healing or to bleomycin-induced skin
fibrosis.
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bleomycin-induced fibrosis that would
reveal important nonredundant roles for
mast cells in such settings is a different
matter.
However, a question that may war-
rant further study is the extent to and the
mechanism by which mast cells can
contribute to wound contraction soon
after full-thickness skin wounding in
mice. Evidence for this was first
provided by Weller et al. (2006) in
their studies of mast cell–engrafted
(WBxC57BL/6)F1-Kit
W/W-v mice, and
findings consistent with this possibility
were obtained by Willenborg et al.
(2014), who found that the separation
of the edges of the panniculous carnosus
at day 3 after full-thickness skin wound-
ing was significantly greater in their
DT-treated mast cell–deficient C57BL/
6-Mcpt5Cre/iDTR mice than in the
corresponding control mice (see
Figure 3B in the study by Willenborg
et al. (2014)). These observations may
not be directly relevant to skin wound
healing in humans, a species in which
most skin lacks a structure correspond-
ing to the panniculus carnosus of
rodents. But the general question of
whether mast cells can influence the
contractility of cells that are thought to
contribute to wound healing or scarring
in other settings (e.g., myofibroblasts)
remains largely unexplored. Similarly,
it remains possible that mast cells
can accelerate the development of
bleomycin-induced skin fibrosis, as a
delay in the development of fibrosis
was noted at week 1 of treatment in
the study by Yamamoto et al. (1999),
but the lesions were not examined until
week 2 in the study by Willenborg et al.
(2014).
Second, it is possible that the
parameters that have been analyzed
to date in skin wound healing or bleo-
mycin-induced skin fibrosis models
have not included features of the
response to which mast cells may
make nonredundant contributions. For
example, mast cells represent rich
sources of proteases that are expressed
to a much lesser extent, or not at all, in
other cell types. It, therefore, may be of
interest to test whether mast cell pro-
teases can express nonredundant func-
tions in these settings.
Third, the fact that a cell lacks a
nonredundant role does not mean that
it has no role. As reviewed in more
detail elsewhere (Reber et al., 2012),
mast cells and other cell types may have
roles in biological responses that overlap
fully or partially with those of other
cells, but are nevertheless important.
By performing such a ‘‘redundant’’
role, mast cells can contribute to the
assessed feature of the response along
with other elements, but the potential
contribution(s) of the mast cell may be
revealed only if one or more of the other
partially redundant or overlapping ele-
ments are impaired. Of course, the more
redundancy that has been engineered
by evolution into a biological response,
the more difficult it may be to identify
the contributions of the individual fully
or partially ‘‘non-redundant’’ elements
of that response.
Finally, there may be differences in
the functions of mast cells, or in the
importance of such mast cell functions
in specific biological settings, e.g., in
different anatomical sites, among mice
of different strains and among mice,
humans, and other species.
In summary, there is no doubt that
mast cells can contribute importantly
to IgE-associated immune responses,
and drive inflammation in the skin and
other sites in which such reactions
occur (Reber et al., 2012). By contrast,
except for what appear to be contribu-
tions to wound contraction (and perhaps
enhanced vascular permeability) at early
stages after skin wounding and a
possible role in hastening the onset of
bleomycin-induced skin fibrosis, the
nature and importance of any other
roles of mast cells in skin wound
healing or bleomycin-induced skin
fibrosis, if any, remain unknown.
This take home message also could be
summarized as follows:
Mast cells clearly can make skin
inflamed,
And in such settings may need to be
tamed.
Can they help heal your wound?
You will need to stay tuned.
Their roles in that have yet to be
named.
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